Data Insights

Cabozantinib s-malate by Exelixis for Metastatic Breast Cancer: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Metastatic Breast Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Metastatic Breast Cancer

Data Insights

Cabozantinib s-malate by Ipsen for Adrenocortical Carcinoma (Adrenal Cortex Cancer): Likelihood of Approval

Cabozantinib s-malate is under clinical development by Ipsen and currently in Phase II for Adrenocortical Carcinoma (Adrenal Cortex Cancer). According...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Adrenocortical Carcinoma (Adrenal Cortex Cancer)

Data Insights

Cabozantinib s-malate by Exelixis for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Pancreatic Ductal Adenocarcinoma

Data Insights

Cabozantinib s-malate by Ipsen for Neuroendocrine Cancer: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Ipsen and currently in Phase II for Neuroendocrine Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Neuroendocrine Cancer

Data Insights

Cabozantinib s-malate by Exelixis for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Recurrent Head And Neck Squamous Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Recurrent Head And Neck Squamous Cell Carcinoma

Data Insights

Cabozantinib s-malate by Exelixis for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)....

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

Data Insights

Cabozantinib s-malate by Exelixis for Soft Tissue Sarcoma: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Soft Tissue Sarcoma

Data Insights

Cabozantinib s-malate by Exelixis for Osteosarcoma: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Osteosarcoma

Data Insights

Cabozantinib s-malate by Exelixis for Endometrial Cancer: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Endometrial Cancer

Data Insights

Cabozantinib s-malate by Exelixis for Metastatic Melanoma: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Metastatic Melanoma

Data Insights

Cabozantinib s-malate by Exelixis for Pheochromocytoma: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Pheochromocytoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Pheochromocytoma

Data Insights

Cabozantinib s-malate by Exelixis for Melanoma: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase I for Melanoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Melanoma

Data Insights

Cabozantinib s-malate by Exelixis for Colorectal Cancer: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Colorectal Cancer

Data Insights

Cabozantinib s-malate by Exelixis for Esophageal Cancer: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Esophageal Cancer

Data Insights

Cabozantinib s-malate by Exelixis for Penile Cancer: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Penile Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Penile Cancer

Data Insights

Cabozantinib s-malate by Exelixis for Esophageal Cancer: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...

Data Insights

Cabozantinib s-malate by Exelixis for Penile Cancer: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Penile Cancer. According to GlobalData, Phase...